May 29, 2018

Chris Bardon Talks to WSJ Pro VC about Late-Stage Combination Therapy Trials

WSJ Pro VC article “Gormley’s Take: Searching for Better Cancer Drug Combinations,” highlights the ongoing search successful immunotherapies and the challenges in predicting success in humans amidst recent clinical trial failures. MPM’s Chris Bardon cites poor animal testing models as a possible contributing factor. (Full article available to WSJ Pro VC Subscribers only)